CAS: 20776-63-0; 2-Amino-4,6-Dichlorobenzoic Acid

上下游产品

CAS号18711-15-4 4,6-二氯靛红 | CAS号1044872-57-2 2-Amino-4,6-dic... | CAS号650598-43-9 2-溴-4,6-二氯苯甲酸

📜4,6-二氯靛红置于双氧水,Sodium Hydroxide,盐酸体系中,用 水 用作溶剂,以82%的收率获得2-氨基-4,6-二氯苯甲酸
参考文献:Novel Substituted-1-H-Quinazoline-2,4-Dione Derivatives,Preparation Method Thereof And Pharmaceutical Composition Containing The Same
标题:Novel Substituted-1-H-Quinazoline-2,4-Dione Derivatives,Preparation Method Thereof And Pharmaceutical Composition Containing The Same
摘要:本文披露了一种新型的取代-1H-喹唑啉-2,4-二酮衍生物,其制备方法以及含有该衍生物的药物组合物.这种新型的取代-1H-喹唑啉-2,4-二酮衍生物在与其他受体相比对5-Ht6受体的结合亲和力和选择性方面表现出色,抑制5-羟色胺(5-Ht)刺激的camp积累,并破坏大鼠中阿波莫啡(2 Mg/kg,I.P.)诱导的过度活动.由于这些效果,这些衍生物在治疗与5-Ht6受体相关的中枢神经系统疾病中非常有用.

专利信息

专利号:US-12319691-B2
优先权日:2020-05-04
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：CZABANIUK LARA C; HOPPER TIMOTHY; HOUZE JONATHAN B; RESCOURIO GWENAELLA; SANTORA VINCENT; WANG HAOXUAN; WHITE RYAN D; WONG ALICE R; WU YONGWEI
权利人:AMGEN INC; VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?).This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-8772301-B2
优先权日:2009-12-18
标题 :Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
发明人：HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D
权利人:HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.